Posted by Michael Wonder on 23 Jun 2026
Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
23 June 2026 - Today, Allergan Aesthetics announced Health Canada has approved Boey (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows (glabellar lines) in adult patients.
Boey is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines.
